Short answer
Axogen, Inc. (AXGN) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $60M (up 23.5% year over year) with net income of $708,000.
Q3 2025 key financials · XBRL
- Revenue
- $60M
- +23.5% YoY · +6.0% QoQ
- Net income
- $708,000
- +138.1% YoY · +22.3% QoQ
- Operating margin
- 3.2%
- Gross margin
- 76.6%
- EPS (diluted)
- $0.01
- +125.0% YoY · +0.0% QoQ
Source: XBRL data from the Axogen, Inc. (AXGN) Q3 2025 10-Q on SEC EDGAR. USD.
Axogen, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk from ongoing U.S. government shutdown starting October 1, 2025, potentially delaying FDA product approvals
- Most material regulatory risk updated: FDA review timing uncertainty for Avance® Nerve Graft BLA, with PDUFA date December 5, 2025
- Operational risk: potential delays in regulatory decisions due to limited FDA resources amid government shutdown
- No new financial risks related to liquidity, debt, currency, or concentration reported since 2024 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axogen, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.